Zhenya Lindgardt is the President and CEO and a Board Director of Sera, Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients.
Prior to joining Sera first as a Board Director in 2021, Zhenya was a member of Executive Leadership team and a C-level executive at Uber Technologies, Inc. in charge of creating new long-term growth businesses on Uber platform, customer engagement and cross-sell across core businesses. In her role at Uber, Zhenya focused on incubating new and scaling current Uber’s two-sided marketplaces and services, driving experimentally proven incremental growth through customer retention and engagement (including cross sell, personalization, portfolio of loyalty programs, subscriptions) across all customer groups.
Before Uber, Zhenya spent 19 years with the Boston Consulting Group (BCG) where she held several operating leadership roles as a Senior Partner and Managing Director of the firm. She was a leadership team member of the largest region (North America, >$5B in revenue) and practice area (Corporate Finance & Strategy, largest for BCG). In healthcare, one of Zhenya’s core areas of focus at BCG, she has worked across the full healthcare industry spectrum from R&D based biopharma and biotech, biomaterials to integrated healthcare systems, pharmacy benefit managers, payers and providers. Breadth of her knowledge of operations of each of these businesses spans from all aspects of operations, as well as corporate, therapeutic area/service line and portfolio strategy and M&A. Therapeutic areas she has expertise in include gene therapy, rare diseases, HIV, oncology, women’s and men’s health, vaccines, ophthalmology, endocrinology and cardiovascular among others.
Zhenya also serves as the CEO of The Commons Project Foundation since 2021, focusing on modernizing industries enabling with their data, starting with health. One of TCP’s flagship products, CommonHealth, is a platform for individuals to access and share all their health data, including wearables, to share with their physicians and family. Broader ongoing monitoring and deploying insights from latest innovations will help clinicians to deliver better quality care and lower overall healthcare costs.
Zhenya received an MBA from Harvard Business School and a bachelor’s degree, cum laude, from the University of Southern California. She lives in San Francisco with her husband and three daughters.
What is Zhenya Lindgardt's net worth?
The estimated net worth of Zhenya Lindgardt is at least $1.73 million as of September 10th, 2026. Ms. Lindgardt owns 837,848 shares of Sera Prognostics stock worth more than $1,734,345 as of September 18th. This net worth estimate does not reflect any other investments that Ms. Lindgardt may own. Learn More about Zhenya Lindgardt's net worth.
How do I contact Zhenya Lindgardt?
Has Zhenya Lindgardt been buying or selling shares of Sera Prognostics?
Over the course of the past ninety days, Zhenya Lindgardt has sold $54,322.00 in shares of Sera Prognostics stock. Most recently, Zhenya Lindgardt sold 7,022 shares of the business's stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $2.00, for a transaction totalling $14,044.00. Following the completion of the sale, the chief executive officer now directly owns 837,848 shares of the company's stock, valued at $1,675,696. Learn More on Zhenya Lindgardt's trading history.
Who are Sera Prognostics' active insiders?
Are insiders buying or selling shares of Sera Prognostics?
In the last twelve months, insiders at the sold shares 39 times. They sold a total of 167,112 shares worth more than $394,436.33. The most recent insider tranaction occured on September, 10th when insider Dyaarl Lee Jr. Anderson sold 1,800 shares worth more than $3,600.00. Insiders at Sera Prognostics own 11.3% of the company.
Learn More about insider trades at Sera Prognostics. Information on this page was last updated on 9/10/2026.
